Your session is about to expire
← Back to Search
Polatuzumab Vedotin for Non-Hodgkin's Lymphoma
Study Summary
This trial will test the safety and efficacy of two different combinations of drugs for people with B-cell non-Hodgkin lymphoma who have either relapsed or are refractory to previous treatment, or who have not been treated before.
- Non-Hodgkin Lymphoma
Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- You have a serious heart or lung condition.You have moderate or severe peripheral neuropathy.Your IPI score is between 2 and 5.You have had an allogeneic stem cell transplant in the past.You have a history of a disease where your body's immune system attacks itself.You have received treatment before for B-cell non-Hodgkin's lymphoma.You have a serious history of liver disease.You have received an organ transplant in the past.You have B-cell non-Hodgkin lymphoma that has come back or hasn't responded to previous treatments.You have received treatment with a drug that targets CD20 before.You have received treatment with mosunetuzumab in the past.You have not received chemotherapy, immunotherapy, or biologic therapy for at least four weeks before starting the clinical trial.You have had or currently have a disease that affects your brain and nervous system, such as stroke, epilepsy, or neurodegenerative disease.
- Group 1: Phase II: Rituxumab (R)-CHP-Pola 1L DLBCL
- Group 2: Phase Ib: M-CHP-Pola Dose-Finding
- Group 3: Phase II: M-CHOP 1L DLBCL
- Group 4: Phase Ib: Mosunetuzumab (M)-CHOP Dose Finding
- Group 5: Phase II: M-CHOP Previously Untreated (1L) DLBCL Safety Cohort
- Group 6: Phase II: M-CHP-Pola 1L DLBCL
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What are some of the most common illnesses that Polatuzumab Vedotin helps patients with?
"Polatuzumab Vedotin is not only useful in the treatment of lung cancers, but also small cell lung cancer (sclc), thyroiditis, and neuroblastoma (nb)."
How many people are currently included in this experiment?
"This specific trial is no longer recruiting patients, as the most recent update was on October 31st, 2022. However, there are 1810 other trials for lymphoma, b-cell and 1285 studies for Polatuzumab Vedotin that are still admitting patients."
Are new participants still being sought for this experiment?
"This specific trial is not searching for new participants right now but there are plenty of other studies that might be a match. According to our records, this study was first posted on February 8th, 2019 and edited last on October 31st, 2022. There are 1810 trials related to lymphoma, b-cell currently recruiting and 1285 trials involving Polatuzumab Vedotin."
How many different staff locations are necessary to manage this study?
"There are 15 sites enrolling patients in this trial. Major cities offering this medication include New york, Miami, and San Francisco."
Are there any historical precedents for using Polatuzumab Vedotin?
"Polatuzumab vedotin was first investigated in 1997 at the Spectrum Health Hospital - Butterworth Campus. As of today, 2065 studies have completed while 1,285 are ongoing. The majority of these active trials are being conducted in Birmingham, Alabama."
To your knowledge, are there other similar trials being conducted?
"Alfacell conducted the first study on Polatuzumab Vedotin in 1997 with 300 participants. After Phase 3 approval, there are currently 1285 studies being conducted in 2829 cities and 79 countries."
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger